thanks board for the clarification.
Looks like my understanding is correct.
"NuSep is moving closer to completing the $15 million funding for PrIME Biologics which will assume a valuation of $50 million for the subsidiary"
Clearly indicates $15m for 30% of PriME, after the transcation, NSP still hold 60%, 60%*50m=$30m
$30m/138m shares= 23c per share plus the upside potential after cashed up...........
Surely this investor is anticipating 100-300% return, if so the upside potential should be $0.23-0.69 per share.
I think this cornerstone investment is most likely from
BAXTER
fair value 23c ready for 400% up, page-24
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MEM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.00M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $25.15K | 5.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 18776263 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 10551662 | 4 |
View Market Depth
| Last trade - 10.32am 08/11/2024 (20 minute delay) ? |
| MEM (ASX) Chart |
